Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Clinical trials news

Show

From To
Should everyone be getting the HIV prevention pill as part of this HIV vaccine study?

More than 500 people have signed up since December to be part of the country’s largest HIV vaccine trial, but some experts are crying foul over what they say is unequal access to the HIV prevention pill among participants.

Published
30 June 2017
From
Bhekisisa
Slow start to landmark South African HIV vaccine trial

Stringent global standards to enlist participants are slowing the process of volunteering to participate in South Africa’s ground-breaking HIV vaccine trial, known as HVTN 702.

Published
02 June 2017
From
Medical Brief
We had to run our own trial for TB drugs – nobody else was doing it

Four years ago, Médecins Sans Frontières (MSF) made the decision to sponsor and run its own tuberculosis clinical trial. The aim was to find a new treatment regimen for drug-resistant tuberculosis (TB) that was radically better than what was currently available. As an organisation that specialises in delivering short-term emergency healthcare, this was a bold and new direction to take. But it was a decision that came from our frustration, anger and impatience on behalf of the more than 20,000 people with TB that we treat every year. We felt compelled to search for improved treatments ourselves because too few pharmaceutical companies, organisations or universities were doing enough about it.

Published
02 June 2017
From
The Guardian
Three countries get first malaria vaccine

The world's first vaccine against malaria will be introduced in three countries - Ghana, Kenya and Malawi - starting in 2018. The four-shot vaccine should prevent four in 10 cases of the disease.

Published
24 April 2017
From
BBC
The New War on Drugs: Trump policy on the FDA

A war against regulations intended to hold manufacturers accountable, protect drug safety and the health of the American public, and advance evidence-based and cost-effective care is questionable at best—and dangerous at worst.

Published
01 April 2017
From
TAG
Mariëtte Botes: ARV pioneer who became the victim of abuse and hostility

Dr Mariëtte Botes, who has died in Pretoria at the age of 50, was an early pioneer of antiretroviral cocktails that saved the lives of hundreds of thousands of people with Aids. But, reports The Times, while running a clinical trial at Kalafong Hospital in Pretoria in 1999, she became the target of a hostile campaign by Patricia de Lille, who was then an MP for the PAC, who accused her of abusing and exploiting her patients.

Published
16 March 2017
From
Medical Brief
What we know about the new England PrEP trial

@teamPrEPster, and other HIV advocate groups, will be keeping a watchful eye on development of the trial, not least to ensure that there are no further delays to its implementation.

Published
27 February 2017
From
Prepster
How to Keep HIV Cure-Related Trials Ethical: The Benefit/Risk Ratio Challenge

While high or unknown risks are a mainstay of early-phase trials in areas like cancer research, cure study participants typically have a safe and efficacious alternative to those risks: remaining on antiretrovirals. Can we justify asking patients who are doing well on antiretrovirals to accept the risk and uncertainty of many HIV cure-related trials? If we cannot, we might need to give up on the hope of curing HIV, or of achieving controlled remission.

Published
22 February 2017
From
BMJ Blogs
New NNRTI doravirine shows good efficacy in phase 3 study

Doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) from Merck, reduced HIV viral load as well as boosted darunavir in a phase 3 clinical trial of

Published
19 February 2017
By
Liz Highleyman
Vaccine trial: Community trust is key

Dr. Linda-Gail Bekker knows from more than 20 years in the field that researchers have to work hand in hand with the communities most affected if they want to halt an epidemic. And the townships are ground zero for HIV/AIDS in Cape Town.

Published
17 February 2017
From
Fred Hutch
← First12345...19Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.